[go: up one dir, main page]

UY31521A1 - SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES - Google Patents

SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES

Info

Publication number
UY31521A1
UY31521A1 UY31521A UY31521A UY31521A1 UY 31521 A1 UY31521 A1 UY 31521A1 UY 31521 A UY31521 A UY 31521A UY 31521 A UY31521 A UY 31521A UY 31521 A1 UY31521 A1 UY 31521A1
Authority
UY
Uruguay
Prior art keywords
epotilones
functioned
solid
polymer nanoparticles
encapsulated
Prior art date
Application number
UY31521A
Other languages
Spanish (es)
Inventor
Dr Sascha General
Dr Katrim Fischer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31521A1 publication Critical patent/UY31521A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen nanopartículas poliméricas con potencial superficial cationico en las cuales pueden encapsularse sustancias neutras, hidrofobicas e hidrofílicas con actividad farmacéutica. Las sustancias hidrofílicas, se encapsulan en la partícula que constituye el nucleo por co-precipatacion, mediante la complejizacion ionica con un polímero cargado.Como sustancias con actividad farmacéutica para la encapsulacion pueden usarse agentes terapéuticos y agentes de diagnostico. La superficie cationica de la partícula permite realizar una modifiacion electrostática estable de la superficie con compuestos con cargas parcialmente opuestas, los cuales pueden contener ligandos con especificidad por el blanco para mejorar el direccionamiento pasivo y activo.Polymeric nanoparticles with cationic surface potential are described in which neutral, hydrophobic and hydrophilic substances with pharmaceutical activity can be encapsulated. The hydrophilic substances are encapsulated in the particle that constitutes the nucleus by co-pre-dissipation, by ionic complexation with a charged polymer.As therapeutic substances for encapsulation, therapeutic agents and diagnostic agents can be used. The cationic surface of the particle allows a stable electrostatic modification of the surface with compounds with partially opposite charges, which may contain ligands with target specificity to improve passive and active addressing.

UY31521A 2007-12-10 2008-12-09 SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES UY31521A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007059752A DE102007059752A1 (en) 2007-12-10 2007-12-10 Functionalized solid polymer nanoparticles containing epothilones

Publications (1)

Publication Number Publication Date
UY31521A1 true UY31521A1 (en) 2009-08-03

Family

ID=40409013

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31521A UY31521A1 (en) 2007-12-10 2008-12-09 SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES

Country Status (7)

Country Link
AR (1) AR069638A1 (en)
DE (1) DE102007059752A1 (en)
PA (1) PA8806901A1 (en)
PE (1) PE20091107A1 (en)
TW (1) TW200932220A (en)
UY (1) UY31521A1 (en)
WO (1) WO2009074274A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
DK2774608T3 (en) 2008-06-16 2020-01-13 Pfizer Drug-loaded polymeric nanoparticles and processes for their preparation and use
WO2010005725A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
EA201100765A1 (en) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Long-term circulation nanoparticles
US20120027821A1 (en) * 2009-03-03 2012-02-02 Public University Corporation Yokohama City University Amino acid-conjugated cyanoacrylate polymer particles
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP2512459A4 (en) * 2009-12-15 2013-08-07 Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
CN103037903A (en) 2010-05-18 2013-04-10 天蓝制药公司 Compositions and methods for treating autoimmune or other diseases
US9610367B2 (en) 2010-08-24 2017-04-04 Canon Kabushiki Kaisha Particle and contrast agent having the particle
MY179194A (en) 2012-09-17 2020-10-30 Pfizer Process for preparing therapeutic nanoparticles
CN105764491A (en) 2013-12-09 2016-07-13 度瑞公司 Pharmaceutically active agent complexes, polymer complexes, and compositions and methods comprising the same
AP2016009494A0 (en) 2014-03-14 2016-10-31 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
AU2015265874B2 (en) * 2014-05-30 2020-05-14 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
DE102017100317A1 (en) 2017-01-10 2018-07-12 Friedrich-Schiller-Universität Jena Nanostructured carrier system for gene delivery
CN115078292B (en) * 2021-03-10 2025-02-11 北京大学 A kind of water-based supramolecular adhesion material and preparation method thereof
EP4577601A1 (en) * 2022-08-22 2025-07-02 Agfa-Gevaert Nv Near infrared and red light absorbing composite resin particles

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US252028A (en) 1882-01-10 Alonzo s
US258286A (en) 1882-05-23 Fruit-drier
US262030A (en) 1882-08-01 Wash-stand
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
AU628988B2 (en) * 1989-05-04 1992-09-24 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors and complexes therefor
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
DE4138042C2 (en) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their production processes and agents containing these compounds
FR2684103B1 (en) 1991-11-22 1994-09-02 Centre Nat Rech Scient NOVEL COMPOUNDS WITH GUANIDIC STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst Methods for in-vivo diagnostics using NIR radiation
ES2178093T5 (en) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) EPOTILON DERIVATIVES AND ITS PREPARATION.
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19728914A1 (en) 1997-07-07 1999-01-14 Basf Ag Metallic colored polyamides
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
AU9799198A (en) * 1997-10-09 1999-05-03 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
DE19820599A1 (en) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh New epothilone derivatives useful as pharmaceuticals and in plant protection
AU4775299A (en) 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
SE517641C2 (en) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Process for making a material layer with barrier tabs and a surface layer with such barrier tabs
JP2000095758A (en) 1998-09-18 2000-04-04 Schering Ag Near-infrared, fluorescent contrast medium, and its production
EP1140944B1 (en) 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
DE19908760A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
DE19908763A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable benzo-fused epothilon derivatives, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
SK11852001A3 (en) 1999-02-18 2002-04-04 Schering Aktiengesellschaft 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19907588A1 (en) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis
WO2000057874A1 (en) 1999-03-29 2000-10-05 Bristol-Myers Squibb Co. A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
AR023792A1 (en) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag DERIVATIVES 6-ALQUENILO- AND 6-ALQUINILO-EPOTILONA, THE PROCEDURES TO PREPARE THEM AND THEIR USE IN PHARMACEUTICAL PRODUCTS
EP1224316A2 (en) 1999-10-08 2002-07-24 Novartis AG 13-alkyl epothilone derivatives
CA2401800A1 (en) 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (en) 2000-04-19 2001-10-25 Schering Ag New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
WO2001092255A2 (en) 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US20020137152A1 (en) 2000-07-25 2002-09-26 Daniel Santi Fermentation process for epothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002213248A1 (en) 2000-10-13 2002-04-22 The University Of Mississipi Synthesis of epothilones and relates analogs
AU2002221693A1 (en) 2000-10-16 2002-04-29 Morphochem Ag Epothilone synthesis components iii and iv: asymmetrically substituted acyloins and acyloin derivatives, method for the production thereof and method for the production of epithilone b, d and epothilone derivatives
AU2002338336A1 (en) 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
DE102005041860A1 (en) * 2005-09-02 2007-03-08 Schering Ag Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
JP2009539793A (en) * 2006-06-08 2009-11-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications

Also Published As

Publication number Publication date
WO2009074274A1 (en) 2009-06-18
TW200932220A (en) 2009-08-01
PA8806901A1 (en) 2009-07-23
PE20091107A1 (en) 2009-08-29
AR069638A1 (en) 2010-02-10
DE102007059752A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
UY31521A1 (en) SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES
WO2014009833A3 (en) Complement pathway modulators and uses thereof
WO2014002051A3 (en) Complement pathway modulators and uses thereof
WO2014002058A3 (en) Complement pathway modulators and uses thereof
HK1206017A1 (en) Complement pathway modulators and uses thereof
WO2007141050A3 (en) Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
BRPI0810899A2 (en) FORMULATION OF ACTIVATED PLGA NANOParticles loaded with ACTIVE AGENT FOR DIRECTIONAL ANTICANETIC NANO-THERAPEUTIC SUBSTANCES.
CR20150523A (en) USE OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS
UA109991C2 (en) CARBAMATE COMPOUNDS, THEIR PREPARATION AND APPLICATION
BR112012006635A2 (en) uniform, rigid, spherical, nanoporous, active agent-loaded calcium phosphate particles and methods of making and using them
BRPI0818673A2 (en) combination therapy of an anti-cd20 type ii antibody with an anti-bcl-2 active agent
BRPI0813680A2 (en) IRNA AGENTS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME, AS WELL AS USE.
EA201590118A1 (en) PYRROLIDINE DERIVATIVES AND THEIR APPLICATION AS MODULATORS OF THE COMPLEMENT ACTIVATION
BR112015011118A2 (en) conjugate; pharmaceutical composition; and use of one or more of the conjugates
LT3360575T (en) TRANSDERMAL PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE AGENTS
FI20116138A7 (en) Matrix for sustained delivery of bioactive agents
GT201200147A (en) MDPI2 ESPIRO-OXINDOL ANTAGONISTS
CO7141411A2 (en) Formulations and methods for vaginal administration of antiprogestins
FR3007969B1 (en) DISPENSER OF A UNITARY DOSE OF AN ACTIVE SUBSTANCE UNDER A SOLID GALENIC FORM
PA8720801A1 (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION
EA201190168A1 (en) THERAPEUTIC APPLICATIONS OF MASTIC RESIN FRACTIONS
TR201907702T4 (en) Triazolopyridine derivatives as modulators of Tnf activity.
PA8796001A1 (en) HISTAMINE H4-FURO-PYRIMIDINE MODULATORS OF THE H4 HISTAMINE RECEIVER
SV2010003694A (en) TIAZOLOPIRIDIN-2-ILOXI-FENIL AND TIAZOLOPIRAZIN-2-ILOXI-FENIL AMINAS AS MODULATORS OF LEUCOTRENE A4 HYDROLASS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171019